Alfuzosin:回顾prolonged-release配方的治疗用途给予一次良性前列腺增生的日常管理。

文章的细节

引用
复制到剪贴板

McKeage K, Plosker GL

Alfuzosin:回顾prolonged-release配方的治疗用途给予一次良性前列腺增生的日常管理。

药。2002;62(4):633 - 53年。

PubMed ID
11893233 (在PubMed
]
文摘

喹唑啉衍生物,Alfuzosin选择性和竞争性α(1)肾上腺素能受体拮抗剂。在前列腺,分配优先与等离子体相比,降低了同情的语气前列腺平滑肌控制。因此降低尿路症状暗示良性前列腺增生(BPH)是改善。每天换一次制定alfuzosin包含不活跃的屏障层已被添加到压缩平板电脑的平面表面。药物释放与常数附近持续超过20小时溶解率2到12个小时。平均值为血浆浓度时间曲线下的面积超过24小时(AUC(24))后被类似管理prolonged-release alfuzosin 10毫克每天一次和速释alfuzosin 2.5毫克,每日3次。同样地,类似的AUC(24)值报告当prolonged-release alfuzosin 10毫克每天一次和缓释alfuzosin 5毫克每日两次比较。这些数据表明,alfuzosin方案提供类似的平均系统性风险。数据从短期(3个月)和长期(12个月)的临床试验表明,prolonged-release制定alfuzosin控制前列腺肥大的症状有效速alfuzosin 2.5毫克,每日三次,和临床改善维持长达1年。改善国际前列腺症状评分、最大尿流率和生活质量指数提高了患者类似的程度上直接或prolonged-release alfuzosin和改进与安慰剂比较,具有统计学意义。 Prolonged-release alfuzosin 10mg is well tolerated and the overall incidence of adverse events is similar to that seen with placebo. The once-daily formulation of alfuzosin 10mg caused fewer vasodilatory adverse events than immediate-release alfuzosin 2.5mg three times daily and caused only slight decreases in systolic and diastolic blood pressure which were not clinically significant and did not differ significantly from those with placebo. No dosage titration is required. The incidence of ejaculatory disorders was <1%. CONCLUSION: Prolonged-release alfuzosin 10mg once daily controls symptoms associated with BPH throughout a 24-hour dosage interval as effectively as immediate-release alfuzosin 2.5mg three times daily but with fewer vasodilatory adverse events. A nonblind extension study showed that clinical benefits were maintained for up to 1 year and the once-daily 10mg formulation continued to be well tolerated, particularly in terms of cardiovascular effects and sexual function. Thus, for the medical management of men with BPH, prolonged-release alfuzosin 10mg is an effective, well tolerated and convenient treatment option.

beplay体育安全吗DrugBank数据引用了这篇文章

药物
药物靶点
药物 目标 类 生物 药理作用 行动
Alfuzosin alpha -肾上腺素能受体(蛋白质组) 蛋白质组 人类
是的
拮抗剂
 细节